Cargando…

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis

Allergic disorders of the ocular surface are primarily characterized as IgE- and/or T-lymphocyte-mediated disorders that affect the cornea, conjunctiva, and eyelid. Approximately 40% of individuals in the developed countries have allergic conjunctivitis, and as such, it is the most common form of oc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chigbu, DeGaulle I, Coyne, Alissa M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501164/ https://www.ncbi.nlm.nih.gov/pubmed/26185412 http://dx.doi.org/10.2147/OPTH.S63790

Ejemplares similares

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Greiner, Jack V, et al.
Publicado: (2011)

Therapeutic Targets in Allergic Conjunctivitis
por: Labib, Bisant A., et al.
Publicado: (2022)

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
por: Ayyappanavar, Shruti, et al.
Publicado: (2021)

Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report
por: Kim, Jae Hyuk, et al.
Publicado: (2019)

Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials
por: McLaurin, Eugene B., et al.
Publicado: (2014)

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
por: Dudeja, Lakshey, et al.
Publicado: (2019)

Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials
por: Ciolino, Joseph B, et al.
Publicado: (2015)

Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval
por: Syed, Yahiya Y.
Publicado: (2023)

A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model
por: Ackerman, Stacey, et al.
Publicado: (2013)

Management of Adenoviral Keratoconjunctivitis: Challenges and Solutions
por: Labib, Bisant A, et al.
Publicado: (2020)

Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis
por: Ono, Santa J, et al.
Publicado: (2011)

A case report of allergic blepharoconjunctivis to alcaftadine
por: Sandrin, Leda Das Neves Almeida
Publicado: (2015)

Pathogenesis and management of adenoviral keratoconjunctivitis
por: Chigbu, DeGaulle I, et al.
Publicado: (2018)

Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives
por: Chigbu, DeGaulle I., et al.
Publicado: (2021)

Pathogenesis and Manifestations of Zika Virus-Associated Ocular Diseases
por: Labib, Bisant A., et al.
Publicado: (2022)

Clinical Management of Herpes Simplex Virus Keratitis
por: Labib, Bisant A., et al.
Publicado: (2022)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra, Ranjan P, et al.
Publicado: (2019)

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%
por: Bergmann, Mark T, et al.
Publicado: (2014)

Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study
por: Gonzalez-Salinas, Roberto, et al.
Publicado: (2021)

A Comparative Study of 0.25% Levobupivacaine, 0.25% Ropivacaine, and 0.25% Bupivacaine in Paediatric Single Shot Caudal Block
por: Sharma, Jagdeep, et al.
Publicado: (2018)

Comparative study of the ocular efficacy and safety of diclofenac sodium (0.1%) ophthalmic solution with that of ketorolac tromethamine (0.5%) ophthalmic solution in patients with acute seasonal allergic conjunctivitis
por: Dehar, Navdeep, et al.
Publicado: (2012)

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

Hepatitis C Virus Infection: Host–Virus Interaction and Mechanisms of Viral Persistence
por: Chigbu, DeGaulle I., et al.
Publicado: (2019)

Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial
por: McLaurin, Eugene, et al.
Publicado: (2018)

Evaluation of Photocatalytic Performance of Nano-Sized Sr(0.9)La(0.1)TiO(3) and Sr(0.25)Ca(0.25)Na(0.25)Pr(0.25)TiO(3) Ceramic Powders for Water Purification
por: Jovanoski Kostić, Aleksandra, et al.
Publicado: (2022)

Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
por: Venkateswaran, Nandini, et al.
Publicado: (2022)

Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
por: Williams, Patricia B, et al.
Publicado: (2010)

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis
por: Cavet, Megan E, et al.
Publicado: (2018)

Effect of over-the-counter brimonidine tartrate 0.025% ophthalmic solution on pupil size in healthy adults
por: Nejad, Mitra, et al.
Publicado: (2021)

Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)
por: Yeu, Elizabeth, et al.
Publicado: (2023)

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
por: Meier, Edward J, et al.
Publicado: (2018)

Caudal Epidural Analgesia in Pediatric Patients: Comparison of 0.25% Levobupivacaine and 0.25% Ropivacaine in Terms of Motor Blockade and Postoperative Analgesia
por: Praveen, P., et al.
Publicado: (2017)

Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis
por: Cervantes, Lorenzo J, et al.
Publicado: (2011)

A Comparative Study of Effect of 0.25% Levobupivacaine with Dexmedetomidine versus 0.25% Levobupivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Block
por: Iyer, Lakshmi S., et al.
Publicado: (2021)

Exchange-bias via nanosegregation in novel Fe(2−x)Mn(1+x)Al (x = −0.25, 0, 0.25) Heusler films
por: Kurdi, S., et al.
Publicado: (2020)

MEF-2 isoforms' (A-D) roles in development and tumorigenesis
por: Madugula, Kiran, et al.
Publicado: (2019)

Peculiar Properties of the La(0.25)Ba(0.25)Sr(0.5)Co(0.8)Fe(0.2)O(3−δ) Perovskite as Oxygen Reduction Electrocatalyst
por: Aliotta, Chiara, et al.
Publicado: (2023)

Potential outstanding physical properties of novel black arsenic phosphorus As(0.25)P(0.75)/As(0.75)P(0.25) phases: a first-principles investigation
por: Liu, Fangqi, et al.
Publicado: (2022)

Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models
por: Tamura, Tadafumi
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ohddrkiqfn0jpjlcg1d7qgh840